This trial investigates a new drug, EIS-12656, in participants with specified advanced
solid tumors carrying pre-specified mutations. The trial consists of a dose escalation
part (Phase 1) and a dose expansion part (Phase 2).
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06525298.
Locations matching your search criteria
United States
Texas
Houston
UT MD Anderson Cancer CenterStatus: Active
Contact: Timothy Anthony Yap
The trial is a Phase 1/2, open label, uncontrolled trial to investigate the safety and
preliminary efficacy of EIS-12656 alone or in combination with a PARPi or T-DXd in
patients with specified advanced or metastatic solid tumors with homologous recombination
deficient (HRD) mutations.
In the Phase 1 dose escalation phase participants will receive ascending doses of
EIS-12656 to evaluate the safety and tolerability and to determine an effective and safe
dose for the Phase 2 part.
In the Phase 2 dose expansion phase participants will either receive EIS-12656
monotherapy at the recommended Phase 2 dose (RP2D) (Module 1) or EIS-12656 in combination
with a PARPi or T-DXd (Modules 2 and 3). The objective is to evaluate the safety and
tolerability and anti-tumor activity of EIS-12656 alone or in combination.
Lead OrganizationEisbach Bio GmbH
Principal InvestigatorTimothy Anthony Yap
